Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors.
Interstitial fluid pressure (IFP) is elevated in tumors due to abnormal vasculature, lack of lymphatic drainage, and alterations in the tumor interstitium. ZD6126 is a tubulin-binding agent that selectively disrupts tumor vasculature resulting in tumor necrosis. This study examined the effect of ZD6126 on tumor IFP and the response of tumors with different IFP levels to ZD6126. Pretreatment IFP was measured using the wick-in-needle method in tumors (murine KHT-C and human CaSki) growing i.m. in the hind legs of mice. Mice were treated i.p. with a single dose of ZD6126 (100 or 200 mg/kg) and posttreatment IFP measurements were made. Blood flow imaging was conducted using Doppler optical coherence tomography, whereas oxygen partial pressure was measured using a fiber optic probe. Clonogenic assays were done to determine tumor cell survival. In KHT-C tumors, IFP dropped significantly at 1 hour posttreatment, returned to pretreatment values at 3 hours, and then declined to approximately 25% of the pretreatment values by 72 hours. In CaSki tumors, the IFP decreased progressively, beginning at 1 hour, to approximately 30% of pretreatment values by 72 hours. Clonogenic cell survival data indicated that ZD6126 was less effective in tumors with high IFP values (>25 mm Hg). Vascular disrupting agents, such as ZD6126, can affect IFP levels and initial IFP levels may predict tumor response to these agents. The higher cell survival in high IFP tumors may reflect greater microregional blood flow limitations in these tumors and reduced access of the drug to the target endothelial cells.
Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada.
Julia V
JV
Skliarenko
Sarah Jane
SJ
Lunt
Maggie L
ML
Gordon
Alex
A
Vitkin
Michael
M
Milosevic
Richard P
RP
Hill
D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D045604:Extracellular Fluid / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005354:Fibrosarcoma / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D006874:Hydrostatic Pressure; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D016513:Mice, SCID; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D010100:Oxygen / Q000378:metabolism; D002583:Uterine Cervical Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*
C455219:N-acetylcochinol-O-phosphate; D009943:Organophosphorus Compounds; D010100:Oxygen